UroGen Pharma Q3 2026 Earnings Call - UROGEN PHARMA LTD

Explicit Guidance:

• FY2026 Net Product Revenue (Gelmido): Updated guidance set at approximately $90 million, reflecting a one-time $1.5 million unfavorable gross-to-net adjustment and headwinds from competitive clinical trials.
• FY2026 Operating Expenses (OpEx): Maintained guidance range of $260 million to $270 million, including $20–$24 million in non-cash share-based compensation; expected to land toward the upper end due to increased investment in education and UGN-103/501 development.
• Zesturi FY2026 Revenue: No full-year guidance provided due to early launch stage; management expects quarter-over-quarter growth in Q4 2026 despite typical holiday seasonality.
• Profitability Timeline: Anticipation to achieve profitability and positive cash flow in Q4 2026.
• Capital Resources: Confident in funding operations through profitability with $90.5 million in cash, cash equivalents, and marketable securities as of Q3 2026.

Business-Segment Outlook:

• Zesturi (Urology):
  • Growth Trajectory: Expects steady linear growth of $15–$20 million per quarter in 2026; outlook for 2027 to maintain steady growth with potential for acceleration.
  • Launch Phase: Focus shifting to driving utilization within 1,500+ activated accounts; unique prescribers at 662 (Q3), repeat prescribers at 50% of total writers (targeting continued increase).
  • DTC Strategy: Full Direct-to-Consumer campaign expected to launch in mid-2027, anticipated to drive an inflection point in adoption.
  • Practice Implementation: Long-term goal to establish "bladder line of service" models in large group practices; currently seeing over 60% of usage as primary therapy (up from adjuvant).
  • Peak Sales: Reiterated long-term peak sales opportunity of $1.2 billion.
• Gelmido (UTUC):
  • Headwinds: Continued pressure from competitive clinical trials in the low-grade UTUC space affecting patient starts; revenue expected to stabilize in the $100–$150 million long-term range.
  • Recovery: Anticipates improvement post-enrollment of UGN-104 Phase III trial (expected complete by end of 2026 or early 2027).
  • Strategy: Plan to deploy a "strike team" to maintain promotional share of voice among heavy users.
• UGN-103 (Next-Gen Zesturi):
  • Commercial Launch: Targeted for 2028, pending permanent J-code assignment by July 1, 2028 (effective Jan 1, 2028).
  • Pipeline Expansion: Planning to initiate a Phase 3 trial for high-grade NMIBC in the fourth quarter of 2026 (adjuvant setting post-BCG).
  • Life Cycle Management: Non-registrational trial for newly diagnosed intermediate-risk NMIBC planned to generate safety/tolerability data.
• Other Pipeline:
  • UGN-104 (UTUC): Enrolment expected to complete by end of 2026 or early 2027.
  • UGN-501 (Oncolytic Virus): Phase I trial dosing commenced; initial clinical data anticipated in 2027.

Market and Competitive Outlook:

• Urology Adoption: Urologists shifting from treating heavily pretreated patients to earlier lines of therapy; adoption driven by clinical efficacy and operational confidence.
• Competition: Active competition in low-grade UTUC space from multiple ongoing Phase III trials, creating near-term patient start headwinds for Gelmido.
• Market Penetration: Targeting ~8,000 urologists total; currently serving ~10% of core target (6,500), indicating significant room for unique prescriber expansion.
• Structural Shift: Continued movement toward "surgery-free" primary treatment paradigms and away from repetitive TURBT interventions.

Macro / Industry Outlook:

• Clinical Trial Environment: Management notes a "surprising" volume of competitive trials in the limited UTUC patient pool, impacting Gelmido demand.
• Regulatory Pathway: FDA engagement for UGN-103 confirmed to require durability data (12-month CRR) and safety; no request for comparative data.
• Reimbursement Dynamics: Continued focus on securing provider confidence regarding buy-and-bill processes and J-codes; management expects reimbursement levels to remain adequate.

Strategic Initiatives:

• Intragel Therapeutics Collaboration:
  • Agreement: Strategic collaboration providing access to Intragel's biodegradable SR-gel platform.
  • Pipeline Access: Opportunity to develop up to three new oncology products; exclusive option to acquire rights to a cisplatin gel for advanced head and neck cancer.
  • Option Trigger: Exercise of option contingent on positive data from Intragel's Phase II study.
  • Timeline: Equity investment of $4 million made in Q3 2026.
• Geographic/Capacity Expansion: Expanding commercial footprint with approx. 160 customer-facing personnel; focusing on expanding presence in community practices (70% of addressable market).
• Technology Expansion: Leveraging RT-GL technology and Intragel's SR-gel to move beyond uro-oncology into other solid tumors.

Risks and Headwinds to Outlook:

• Gelmido Competition: Enrollment in competing low-grade UTUC clinical trials is a material headwind for Gelmido patient starts.
• Seasonality: Anticipated summer seasonality (Q3) and holiday-related slowdowns (Q4) may cause quarterly volatility.
• Launch Execution: Zesturi adoption relies on physician familiarity and operational workflow integration; adoption speed may be slower than historical benchmarks due to methodical nature of urologists.
• Regulatory Uncertainty: UGN-103 timeline dependent on FDA review of 12-month durability data and successful J-code assignment.
• One-Time Items: Q3 results impacted by $1.5M gross-to-net adjustment (Gelmido), $4.8M PDUFA fee, and $4M Intragel investment.

Management Tone on the Future:

• Confidence: High confidence in reaching profitability in Q4 2026 and sustained growth through commercial execution and pipeline advancement.
• Forward-Looking Sentiment: Optimistic regarding the inflection point driven by DTC launch in 2027 and the transition to UGN-103 in 2028.
• Strategic Focus: Emphasis on "depth" of utilization in existing accounts and "breadth" of adoption across new prescribers; management views the current early-stage launch as having significant runway.
• Hedging: Repeated disclaimers on forward-looking statements regarding risks found in SEC filings; guidance for Zesturi 2027 remains unissued pending further clarity on quarterly dynamics.

Miscellaneous:

• Patent Protection: Newly issued patent listed in FDA Orange Book extends coverage to July 2044 for Zesturi and UGN-103 (for low-grade intermediate-risk NMIBC).
• Cash Position: $90.5 million in cash and equivalents; accounts receivable of $117 million.
• Clinical Data: UGN-103 Phase 3 (Utopia) results consistent with Zesturi (3-month complete response); Gelmido 5-year follow-up shows 75% event-free survival at median 53.3 months.